WALTHAM, Mass. - Aerovate Therapeutics, Inc. (NASDAQ: AVTE), a biopharmaceutical company specializing in treatments for rare cardiopulmonary diseases, announced today the appointment of Habib Dable as the new Chair of its Board of Directors. Mr. Dable, who has been a member of Aerovate's board since July 2023, will take over from Mark Iwicki, with the latter continuing his service on the board.
Tim Noyes, CEO of Aerovate, expressed confidence in Dable's leadership, particularly as the company anticipates the Phase 2b data readout from the IMPAHCT trial of AV-101 in Pulmonary Arterial Hypertension (PAH) in June and progresses with its Phase 3 trial. Noyes also acknowledged Iwicki's significant contributions to the company.
Dable brings a wealth of experience to his new role, having previously led Acceleron Pharma (NASDAQ:XLRN), Inc., which was sold to Merck & Co. for $11.5 billion in 2021. His earlier tenure at Bayer AG (ETR:BAYGN) saw him successfully launch several brands, including EYLEA®, Stivarga®, and Xofigo®.
AV-101, Aerovate's investigational drug, is a dry powder inhaled formulation of imatinib, designed to target cellular hyperproliferation and resistance to apoptosis in PAH. The drug aims to improve patient outcomes beyond current therapies by delivering medication directly to the lungs, minimizing systemic side effects. Phase 1 results indicated that AV-101 was generally well-tolerated by healthy adult volunteers.
The IMPAHCT trial is a multi-national, placebo-controlled study transitioning from Phase 2b to Phase 3, assessing the safety and efficacy of AV-101 in adults with PAH. The trial's primary endpoints include changes in pulmonary vascular resistance and six-minute walk distance.
The information in this article is based on a press release statement from Aerovate Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.